TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25246338
Drug: No stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No stem cell therapy (Control group)
Study: 20102716
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg, orally, 3 times daily)
Study: 11966970
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (active and passive jaw movement exercises, correction of body posture, relaxation techniques)
Study: 11966970
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control (no treatment)
Study: 7594322
Drug: Lansoprazole plus
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole plus low-dose amoxicillin
Study: 7594322
Drug: Lansoprazole monotherapy
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole monotherapy
Study: 31743412
Drug: Arrowhead Business
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arrowhead Business Group (ABG) entrepreneurship education intervention; details on dosage and duration not available.
Study: 15511696
Drug: Zonisamide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (400 mg QD)
Study: 8036045
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate 40 mg/kg/day
Study: 8036045
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate 25 mg/kg/day
Study: 2838288
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with chemotherapy (RT-CT)
Study: 25766448
Drug: Cumin cyminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumin cyminum L. capsule (n = 26)
Study: 25766448
Drug: Orlistat120 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat120 capsule (n = 26)
Study: 18474492
Drug: ENF 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENF 180 mg qd
Study: 18474492
Drug: ENF 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENF 90 mg bid
Study: 16401645
Drug: 200mg G115/0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg G115/0 mg glucose (ginseng)
Study: 16401645
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg G115/25 g glucose (glucose)
Study: 16401645
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg G115/25 g glucose (ginseng/glucose combination)
Study: 16401645
Drug: 0mg G115/0
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg G115/0 mg glucose (placebo)
Study: 12853380
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of slow-release clarithromycin
Study: 27121185
Drug: Basic body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic body awareness treatment
Study: 25014001
Drug: Escitalopram (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10‐20 mg/d)
Study: 18853315
Drug: Chloramphenicol 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 0.2% with polymyxin B 2500 U/ml
Study: 15339466
Drug: Fufang Sishen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Sishen Decoction (FFSSD), 6 g, b.i.d.
Study: 15339466
Drug: Propafenone, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone, 150 mg, q 8 h
Study: 9647301
Drug: Raised antiviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raised antiviral antibody titres
Study: 2678834
Drug: DDP in
Normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP in combination with adriamycin (ADM) and cyclophosphamide
Study: 26860808
Drug: Flaxseed (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (25 g daily)
Study: 26860808
Drug: Vitex agnus
Normalized name: VITEX AGNUS-CASTUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitex agnus (3.2‐4.8 mg daily)
Study: 24225451
Drug: MNP+Zn (Micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: MNP+Zn (Micronutrient Powder with 10 mg of zinc)
Study: 22431798
Drug: WC2031 (doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: WC2031 (doxycycline hyclate delayed-release 200-mg tablet) orally once daily for 7 days
Study: 22431798
Drug: Vibramycin (doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibramycin (doxycycline hyclate capsule) 100 mg orally twice daily for 7 days
Study: 18705027
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release 250 mg once daily
Study: 18705027
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release 500 mg once daily
Study: 18705027
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release 1000 mg once daily
Study: 8971298
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg body weight of midazolam
Study: 1611111
Drug: 100 MU
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Study: 1611111
Drug: 10 MU
Normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Study: 1611111
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (10 MU)
Study: 1611111
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (100 MU)
Study: 6704008
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% betaxolol
Study: 31653510
Drug: Vaccine-KLH conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaccine-KLH conjugate + OPT-821
Study: 25108545
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 50 mcg
Study: 16234333
Drug: 0.5 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 h infusion of 0.5 g every 6 h
Study: 16234333
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h infusion of 0.5 g every 6 h
Study: 16234333
Drug: 2 h
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 h infusion of 1 g every 6 h
Study: 11834876
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg over 10 min)
Study: 11834876
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (0.1 microg/kg/min over 60 min)
Study: 3605131
Drug: Extra snack
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra snack at bedtime if capillary blood glucose levels at 10:30 P.M. were 120 mg/dl or less
Study: 20572368
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐estradiol (50 mg/day) and medroxy progesterone acetate (2.5 mg/day) for 3 months
Study: 20572368
Drug: Placebo (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (both transdermal and oral)
Study: 18323719
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education program (5 monthly sessions)
Study: 11290878
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigabatrin (VGB) 2,000 mg
Study: 30136291
Drug: Oral taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral taurine supplementation (2 g/day)
Study: 27428211
Drug: Vaginal rings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal rings containing 25 mg dapivirine (DPV)/100 mg maraviroc (MVC)
Study: 25456370
Drug: Everolimus (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (4.5 mg/m² per day, adjusted for tolerability to attain blood trough concentrations of 5-15 ng/mL)
Study: 22592573
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron in saline
Study: 22592573
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol in saline
Study: 9436865
Drug: Combination (Ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (Ethanol + Nifedipine)
Study: 1204278
Drug: Nabilone 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 2.5 mg
Study: 1204278
Drug: Nabilone 5
Normalized name: nabilone 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 5 mg
Study: 1204278
Drug: Nabilone 1
Normalized name: nabilone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 1 mg or 2 mg two times daily
Study: 1204278
Drug: Nabilone 5
Normalized name: nabilone 500 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone 5 mg after 7-day drug period
Study: 31948903
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg plus placebo every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Study: 31948903
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Study: 31058448
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid injection (100 mL/5 mg) after operation, along with oral calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Study: 31058448
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Study: 21584942
Drug: tofacitinib 1
Normalized name: tofacitinib 11 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 1 mg twice a day
Study: 21584942
Drug: tofacitinib 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 3 mg twice a day
Study: 21584942
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg twice a day
Study: 21584942
Drug: tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 10 mg twice a day
Study: 10827213
Drug: High fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fruit and vegetable diet (500g daily)
Study: 10827213
Drug: Low fruit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fruit and vegetable diet (100g daily)
Study: 8893577
Drug: 99mTc-labeled monoclonal
Normalized name: technetium (99mTc) exametazime labelled cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-labeled monoclonal granulocyte antibody scintigraphy
Study: 8893577
Drug: 99mTc-labeled monoclonal
Normalized name: technetium (99mTc) exametazime labelled cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-labeled monoclonal granulocyte antibody scintigraphy combined with tomographic scan
Study: 1671468
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide and oral prednisone (n = 55)
Study: 1671468
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral cyclophosphamide, alternate day prednisone (22 weeks), and weekly plasma exchange (20 weeks) (n = 57)
Study: 1671468
Drug: Placebo medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medications and sham plasma exchange (n = 56)
Study: 6839914
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid regimen (172 +/- 25 ml/kg/day)
Study: 6839914
Drug: Low fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluid regimen (121 +/- 13 ml/kg/day)
Study: 31533539
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance group
Study: 24977716
Drug: Atomoxetine (80-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (80-100 mg/d)
Study: 15764277
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (betamethasone), applied twice daily for 4 weeks
Study: 15764277
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (betamethasone) after 4 weeks for non-responders
Study: 12475833
Drug: HFA‐BDP, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐BDP, 80 micro g/d
Study: 12475833
Drug: HFA‐BDP, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐BDP, 160 micro g/d
Study: 3401697
Drug: OWLS (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: OWLS (oral and written language training)
Study: 3401697
Drug: Classroom survival
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classroom survival skills (alternative treatment control)
Study: 30625189
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (BCP + B. infantis)
Study: 27837387
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (≤3 doses of 100,000 IU)
Study: 27837387
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) with maintenance dose (3420 IU/day)
Study: 27837387
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D3 (loading dose)
Study: 23424159
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN β‐1a 30 μg intramuscularly weekly + glatiramer acetate 20 mg daily)
Study: 23424159
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN + GA)
Study: 21955196
Drug: Ramelteon (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (all doses)
Study: 21955196
Drug: Ramelteon (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon (up to 8 mg)
Study: 19203773
Drug: Free iron/folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free iron/folic acid tablets (IFA)
Study: 19203773
Drug: Routine prenatal
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prenatal visits with prescriptions to purchase IFA
Study: 11695069
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg morning, 500 mg evening
Study: 9137848
Drug: Lamotrigine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (200 mg/day, with slow dose-escalation starting at 25 mg/day for 2 weeks, then 50 mg/day for 2 weeks)
Study: 7899583
Drug: High-dose 1‐alpha‐OHD3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose 1‐alpha‐OHD3 plus 24,25(OH)2D3 (2 x 5 micrograms/day)
Study: 7899583
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with 1‐alpha‐OHD3
Study: 3035960
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of fenoterol (50 micrograms, 2 puffs, 4 times a day for 2.5 weeks)
Study: 2198436
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of olestra twice a day
Study: 26044291
Drug: Oral Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Tenofovir Disoproxil Fumarate (TDF)
Study: 26044291
Drug: Vaginal Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal Tenofovir (TFV) gel
Study: 26044291
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral or vaginal)
Study: 23704191
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (3 μg kg(‐1)) plus wound infiltration with 30 ml of 0.25% bupivacaine
Study: 23704191
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 3 μg kg(‐1) clonidine plus 30 ml of 0.25% bupivacaine
Study: 23704191
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (wound infiltration with 30 ml of 0.25% bupivacaine)
Study: 23704191
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (3 μg kg(‐1))
Study: 23704191
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 3 μg kg(‐1) clonidine
Study: 17200793
Drug: Family Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Therapy
Study: 15161773
Drug: Repaglinide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (0.5 mg/meal, maximum dose 4 mg/meal)
Study: 15161773
Drug: Nateglinide (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (60 mg/meal, maximum dose 120 mg/meal)
Study: 3364800
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (AI) after placebo (Pl) pretreatment
Study: 3364800
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (AI) after diltiazem (D) pretreatment
Study: 3364800
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (AI) after verapamil (V) pretreatment
Study: 21177180
Drug: Cisatracurium infusion
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium infusion with continuous monitoring of T1, adjusted according to muscle relaxation monitoring.
Study: 8597678
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen 625 micrograms daily alone
Study: 8597678
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine oestrogen 625 micrograms daily plus norgestrel 150 micrograms daily for the last 12 days of the 'cycle'
Study: 6760961
Drug: Weekly BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly BCG and leukemia cell vaccine (group 1)
Study: 6760961
Drug: Monthly BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly BCG and leukemia cell vaccine (group 2)
Study: 6760961
Drug: Monthly BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly BCG with no leukemia cell vaccine (group 3)
Study: 29914954
Drug: LR-BAC (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR-BAC (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Study: 29914954
Drug: LR-BAT (Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: LR-BAT (Low dose rabeprazole 10 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Study: 29914954
Drug: HR-BAC (High
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR-BAC (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + clarithromycin)
Study: 29914954
Drug: HR-BAT (High
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR-BAT (High dose rabeprazole 20 mg b.i.d. + bismuth + amoxicillin + tetracycline)
Study: 15803051
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus IVIG (Pentaglobin; 7 mL/kg/day for 5 days)
Study: 15803051
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus 5% human albumin (control group)
Study: 2218657
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (CAE), 30 mg/kg/day
Study: 2218657
Drug: Cefaclor (CEC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (CEC), 40 mg/kg/day
Study: 2218657
Drug: Amoxicillin-clavulanate potassium
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate potassium (AMX-CL), 40 mg/kg/day
Study: 2218657
Drug: Amoxicillin-clavulanate potassium
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate potassium (AMX-CL)
Study: 348125
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium glucose electrolyte solution (sodium concentration of 50 mmol/l)
Study: 348125
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral solution (sodium concentration of 90 mmol/l)
Study: 23281658
Drug: Ramosetron 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 6 μg·kg(‐1)
Study: 23281658
Drug: Ondansetron 100
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 100 μg·kg(‐1)
Study: 23281658
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received intravenous patient-controlled analgesia with fentanyl
Study: 22106196
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin plus normal saline wound irrigation
Study: 22106196
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin plus Microcyn Rx wound irrigation
Study: 17585038
Drug: 25 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g/d of FS
Study: 17585038
Drug: 50 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/d of FS
Study: 17585038
Drug: 72 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 72 g/d of CSB